Pharmacotherapy of Pediatric Attention-Deficit/Hyperactivity Disorder

Brigette Vaughan, Christopher J. Kratochvil

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations


This article describes the practical use of available attention-deficit/hyperactivity disorder (ADHD) pharmacotherapies, their formulations and durations of action, and the extent of Food and Drug Administration approvals. It provides data on short-term and long-term safety of these medications, their use in ADHD with comorbid conditions, and strategies for formulating individualized, effective, and well-tolerated pharmacotherapy treatment plans. A clinical vignette focusing on a male child with ADHD is presented. Summaries are presented of ADHD pharmacotherapies and Food and Drug Administration approval status, atomoxetine and stimulant comparator trials, adverse effects and ADHD pharmacotherapy, and delivery system and duration of effect.

Original languageEnglish (US)
Pages (from-to)941-955
Number of pages15
JournalChild and Adolescent Psychiatric Clinics of North America
Issue number4
StatePublished - Oct 2012


  • ADHD
  • Amphetamine
  • Atomoxetine
  • Clonidine
  • Guanfacine
  • Methylphenidate
  • Pharmacotherapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health


Dive into the research topics of 'Pharmacotherapy of Pediatric Attention-Deficit/Hyperactivity Disorder'. Together they form a unique fingerprint.

Cite this